John McHutchison joins the Board of Evox Therapeutics
Highly experienced life sciences executive that brings large pharma and biotech experience
News provided by
Share this article
Share this article
OXFORD, England, Jan. 18, 2021 /PRNewswire/ Evox Therapeutics Ltd ( Evox or the Company ), a leading exosome therapeutics company, today announces that John McHutchison has joined its Board of Directors. John will be joining the Board as the representative for Oxford Sciences Innovation (OSI), one of the Company s major shareholders. John is a highly experienced life sciences executive, with expertise across multiple therapeutic areas, particularly infectious diseases and diseases of the liver and gastrointestinal tract.
Corona-News: Mehr als 18 000 neue Corona-Infektionen in Deutschland
mopo.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mopo.de Daily Mail and Mail on Sunday newspapers.
RH: Catch Up with Cameron Ledford - Wichita State Athletics
goshockers.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from goshockers.com Daily Mail and Mail on Sunday newspapers.
News Category Global Banking & Finance Reviews
Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced Melanoma
Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced Melanoma Istari Oncology, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for PVSRIPO for the treatment of advanced melanoma (stage IIB-IV). PVSRIPO is a novel viral immunotherapy, based on the Sabin type 1 polio vaccine, that activates a patients innate and adaptive immune system to facilitate an anti-tumor response and establish long-term immunologic memory to help prevent the cancers return.